Document:

exv10w101

 

Exhibit 10.101

AMENDMENT NUMBER 3

TO

DEVELOPMENT AND SUPPLY AGREEMENT DATED DECEMBER 28, 2001

BETWEEN

ABBOTT LABORATORIES

 AND INTERMUNE, INC.

     This Amendment No. 3, to the Development and Supply Agreement dated as of December 28, 2001,
as amended by Amendment No. 1 dated April 26, 2002, Amendment No. 2 dated October 15, 2002, and the
letter agreement regarding “Authorization for Disclosure of Confidential Information” dated July
18, 2003 (collectively, the “Agreement”), is effective as of December 22, 2005 (“Amendment No. 3
Effective Date”) between Abbott Laboratories, an Illinois corporation (“Abbott”), and InterMune,
Inc., a Delaware corporation (“InterMune”). Any capitalized term used and not otherwise defined
herein shall have the meaning set forth in the Agreement.

     WHEREAS, the parties desire to amend the Agreement as set forth below.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements
contained herein, the parties hereto, intending to be legally bound, hereby agree as follows:

	 	1.	 	Amendment. Abbott and InterMune hereby amend the Agreement as follows:

	 	A.	 	Section 8.6 of the Agreement is amended and restated as
follows:

     8.6 Non-Standard Equipment or Additional Capacity. If equipment
is required to manufacture Bulk Drug Substance for InterMune, InterMune
shall pay the cost of such equipment, subject to InterMune’s prior approval
of such costs, which approval shall not be unreasonably withheld. Abbott
shall advise InterMune of equipment required and the estimated cost(s)
associated with the purchase, installation and validation of such equipment.
Such equipment shall be used exclusively for manufacturing Bulk Drug
Substance hereunder or, if utilized for other products, such cost(s) shall
be prorated accordingly. Abbott shall bill InterMune for the associated
costs after Abbott installs the equipment.

	 	B.	 	Section 12.1 of the Agreement is amended and restated as
follows:

     12.1 Term. This Agreement shall become effective as of the
Effective Date, and unless sooner terminated hereunder, shall continue in
effect until December 31, 2014; provided, however, that twenty-four (24)
months prior written notice of a party’s intent to terminate this Agreement
is given to the other party. THEREAFTER, THIS AGREEMENT SHALL STAY IN
EFFECT FOR RECURRENT ADDITIONAL TWO (2) YEAR PERIODS, UNLESS TWELVE (12)
MONTHS PRIOR WRITTEN NOTICE OF A PARTY’S INTENT TO TERMINATE IS GIVEN TO THE
OTHER PARTY.

 

 

	 	C.	 	A new Section 12.6 of the Agreement is hereby added to the
Agreement and shall read as follows:

     12.6 Abbott Termination of Rights. In the event InterMune fails
to obtain NDA approval by January 1, 2010, Abbott shall have the right to
terminate this Agreement.

	 	D.	 	A new Section 12.7 of the Agreement is hereby added to the
Agreement and shall read as follows:

     12.6 Actions on Termination.

	 	(a)	 	Upon expiration or termination of
this Agreement for any reason by InterMune, upon InterMune’s
request, Abbott will reasonably assist InterMune with the
technology transfer of the manufacturing process associated with
Bulk Drug Substance to InterMune or its designee, and InterMune
shall pay Abbott’s reasonable costs and expenses for such
assistance.
	 
	 	(b)	 	Upon termination of this
Agreement for any reason by Abbott, upon InterMune’s request,
Abbott will reasonably assist InterMune with the technology
transfer of the manufacturing process associated with Bulk Drug
Substance to InterMune or its designee, and Abbott shall pay
Abbott’s reasonable costs and expenses for such assistance.

	 	2.	 	Miscellaneous.

	 	A.	 	All terms and conditions set forth in the Agreement that are
not amended hereby shall remain in full force and effect.
	 
	 	B.	 	This Amendment shall be governed by and construed in accordance
with the substantive law of the State of New York, without regard to the
conflicts of law provisions thereof, and any dispute arising out of or in
connection with this Amendment shall be governed by the alternative dispute
resolution provisions of Exhibit E of the Agreement.
	 
	 	C.	 	This Amendment may be executed in counterparts, each of which
shall be deemed an original, but all of which will constitute one and the same
instrument.
	 
	 	D.	 	Any term of this Amendment may be amended with the written
consent of both parties.

2

 

	 	E.	 	This Amendment is the product of both of the parties hereto,
and together with the Agreement constitutes the entire agreement between such
parties pertaining to the subject matter hereof, and merges all prior
negotiations and drafts of the parties with regard to the matters set forth
herein.
	 
	 	F.	 	From the date hereof, any reference to the Agreement shall be
deemed to refer to the Agreement as amended by this Amendment.

     IN WITNESS WHEREOF, the parties, through their authorized officers, have executed this
Amendment as of the Amendment No. 3 Effective Date.

	 	 	 	 	 
	InterMune, Inc.

	 	ABBOTT LABORATORIES
	 	 
	 
	 	 	 	 
	/s/ Thomas Kassberg

	 	/s/ Mike L. McGibbon	 	 
	 

	 	 	 	 
	Name:Thomas Kassberg

Title: Senior Vice President

	 	Name: Mike L. McGibbon

Title: General Manager, Pharma	 	 

3exv10w102

 

Exhibit 10.102

certain material (indicated by an asterisk) has been omitted from this document pursuant to a
request for confidential treatment. the omitted material has been filed separately with the
securities and exchange commission.

Amendment No. Four to License and Commercialization Agreement

This AMENDMENT NO. FOUR TO LICENSE AND COMMERCIALIZATION AGREEMENT (the “Amendment No. Four”)
is made effective as of December 22nd, 2005 (the “Amendment Effective Date”), and is
entered into by and between AMGEN INC., a Delaware corporation having its principal place of
business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and INTERMUNE, INC., a
Delaware corporation having its principal place of business at 3280 Bayshore Blvd., Brisbane, CA
94005 (“InterMune”). Amgen and InterMune are sometimes referred to herein individually as a
“Party” and collectively as the “Parties,” and references to “InterMune” and “Amgen” shall include
their respective Affiliates. All capitalized terms used herein shall have the meaning given to
them in the Original Agreement (as defined below) unless otherwise defined herein.

Background

     WHEREAS, the Parties entered into that certain License and Commercialization Agreement
effective as of June 15th, 2001, as amended (the “Original Agreement”) pursuant to which
Amgen granted certain rights to InterMune relating to the Licensed Products; and

     WHEREAS, the Parties now desire to further amend the Original Agreement.

     NOW THEREFORE, based on the foregoing premises and the mutual covenants and obligations set
forth below, and for good and valuable consideration, the receipt and sufficiency of which the
Parties hereby acknowledge, the Parties hereby agree as follows:

1. The following shall be added to the Original Agreement as a new Section 2.3(i):

“(i) Amgen hereby grants to InterMune an exclusive [***] license
under Amgen’s entire right, title and interest in and to the
internet domain name <infergen.com>, with the right to grant
sublicenses (subject to InterMune’s compliance with Section 2.5 of
this Agreement), to link to such domain name solely on InterMune’s
website, and to use such domain name solely in connection with the
Licensed Products in the Territory. InterMune shall reasonably
consider any comments that Amgen or Other Licensees may have with
respect to the <infergen.com> website and content thereof.
InterMune shall be solely responsible for maintaining the internet
domain name <infergen.com>, including payment of any domain
name maintenance fees, and for making all content on the
<infergen.com> website complete, accurate and not misleading
at all times. InterMune shall use commercially reasonable efforts
to prevent any obscene or offensive content, or content that
disparages Amgen, Other Licensees or Licensed
Products, from being placed on or associated with such website
and domain name. InterMune shall Indemnify Amgen and its
Affiliates, agents, directors, officers, and employees from and

 

*** Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

Page 1 of 3

 

against any and all Losses arising from Third Party claims
resulting directly or indirectly from InterMune’s use of the
<infergen.com> domain name or operation of the
<infergen.com> website, including but not limited to the
content thereof. Upon request by Amgen, InterMune will promptly
take all actions necessary to remove any use of Amgen’s name on the
website located at <infergen.com> to which Amgen objects.
InterMune will also clearly identify itself on the website as the
party controlling the operation of such website.””

2. The first paragraph of Exhibit 2 Amgen Materials (Cell banks and Reference Standards)
(which is attached to Amendment Number 2 to License and Commercialization Agreement dated
December 31, 2004), is hereby amended in its entirety as follows:

“[***].”

This Amendment No. Four is intended by the Parties to amend the Original Agreement only to the
extent of the specific amendment set forth above. This Amendment No. Four, and the Original
Agreement (collectively, the “Transaction Agreements”), set forth the complete, final and exclusive
agreement with respect to their subject matter and all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties hereto with respect
to such subject matter and supersede and terminate all prior agreements and understandings between
the Parties with respect to such subject matter. There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or written, between the
Parties with respect to such subject matter other than as are set forth in the Transaction
Agreements.

3. This Amendment shall be governed by and interpreted in accordance with the substantive laws of
the State of California and the Parties hereby submit to the jurisdiction of the California courts,
both state and federal.

 

*** Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

Page 2 of 3

 

4. No amendment, modification or supplement of any provision of this Amendment shall be valid or
effective unless made in writing and signed by a duly authorized officer of each Party.

5. This Amendment may be signed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.

6. InterMune, Amgen, Valeant Pharmaceuticals North America and Valeant Pharmaceuticals
International have entered into that certain Consent to Assignment Agreement dated November 23,
2005 (“Consent”). The Parties acknowledge and agree that this Amendment shall be deemed a part of
the Agreements, as that term is defined in the Consent.

IN WITNESS WHEREOF, the Parties have executed this Amendment No. Four in duplicate originals by
their duly authorized representatives as of the Amendment Effective Date.

	 	 	 	 	 	 	 	 	 
	AMGEN INC.	 	 	 	INTERMUNE, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Scott J. Foraker
	 	 	 	By:
	 	/s/ Robin Steele
	 

	 	 
	 	 	 	 	 	 
	Name: Scott J. Foraker, Esq.	 	 	 	Name: Robin Steele
	Title: Vice President, Licensing	 	 	 	Title: Senior Vice President & General Counsel
	Date: 12/22/05	 	 	 	Date: 12/22/05

Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]